Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, utilizing its PRISM platform to develop treatments for disorders like Duchenne muscular dystrophy and Huntington’s disease. Founded in 2015, it employs 266 people and is advancing RNA-targeting modalities such as editing and interference.
WVE has been in the news recently: WAVE Life Sciences is not directly mentioned in the provided information, but QIAGEN N.V. plans to release its fourth-quarter 2024 results on February 5, with a conference call scheduled for February 6. Additionally, TetraScience has partnered with Microsoft to enhance AI workflows in biopharmaceuticals, which may indirectly relate to the broader industry context in which WAVE Life Sciences operates.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
